Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

MRI-US Fusion Targeted Biopsy Better Determines Prostate Cancer Significance, Risk

May 14th 2016

Herbert Lepor, MD, discusses the advent of the MRI-US fusion targeted biopsy and what impact it could have on the field of assessing prostate cancer risk.

HIFU Demonstrates Significant Role in Prostate Cancer

May 13th 2016

Results of a multi-institutional prospective study showed that treatment with unilateral high-intensity focused ultrasound led to eradication of all clinically significant cancer in the treated lobe for 94% of patients with early prostate cancer.

Biomarker Assay as Alternative to Early-Stage Prostate Cancer Detection

May 12th 2016

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Radium-223/Abiraterone Combo Improves QOL, Bone Pain in mCRPC

May 12th 2016

The combination of radium-223 dichloride (Xofigo) and abiraterone acetate (Zytiga) was associated with significant reductions in bone pain, as well as improvements in quality of life, in patients with metastatic castration-resistant prostate cancer.

Task Force PSA Recommendation Challenged Following Analysis

May 11th 2016

Major health policy implications follow findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial, after it was found that 80% of the control group reported at least one PSA test during the trial.

Steroid Use With Abiraterone Offers Multidimensional Benefits to Patients With mCRPC

May 4th 2016

Abiraterone acetate, alone or in combination with low-dose steroids, has been intensely investigated in recent years for the treatment of progressive CRPC in patients who have received prior chemotherapy or who were treatment-naÃ¯ve.

Fred Schumacher on Genetic Risk Factors of Prostate Cancer

May 3rd 2016

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Enzalutamide Pricing Debate Goes to Washington

May 1st 2016

Enzalutamide (Xtandi) pricing heightens the likelihood of pre-authorization requirements and cost-sharing arrangements that may be financially burdensome, ruinous, or simply impossible to meet.

Preventing and Treating Bone Metastases in mCRPC

April 30th 2016

Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC

April 26th 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

April 25th 2016

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Analysis of Real-World Data for Next-Generation Antiandrogen Therapies

April 25th 2016

Real-world data obtained from large retrospective studies can also deliver useful insights into the clinical challenges associated with newer therapies in prostate cancer, such as medication adherence and cognitive adverse events.

Dr. Stock on the Optimal Use of Radium-223 in mCRPC

April 25th 2016

Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.

Optimal Sequencing Explored for Enzalutamide and Abiraterone in mCRPC

April 22nd 2016

Although abiraterone acetate (Zytiga) and enzalutamide (Xtandi) have demonstrated improved survival outcomes, the optimal sequencing of these therapies has not been established, and most patients exhibit some degree of cross-resistance.

Radium-223 Combinations on Horizon in mCRPC

April 21st 2016

Oliver Sartor, MD, discusses the combination regimens being explored with radium-223, its unique mechanism of action, and the associated risks and benefits.

Experts Discuss Treatment Sequencing Strategies in CRPC

April 19th 2016

E. David Crawford, MD, and Leonard G. Gomella, MD, provide insight into current best practices and strategies that are on the horizon in metastatic castration-resistant prostate cancer.

Addressing Therapeutic Challenges for Geriatric Patients With mCRPC

April 15th 2016

Clinicians must consider and evaluate the unique characteristics and treatment options for older men with prostate cancer, who are more likely to be diagnosed with advanced disease, and tend to have higher mortality rates and poorer prognosis.

Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines

April 1st 2016

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.

Dr. Gomella on Current Perspectives on Prostate Cancer Screening

April 1st 2016

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.

Gomella Discusses Radium-223 Impact in mCRPC

March 23rd 2016

Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.